
Top Stories 
Published On January 15, 2014
CLINICAL RESEARCH
In Framingham, Deep Cuts
Sharply pared budgets could kill the Framingham Heart Study—after 50 years of astonishing research breakthroughs.
In 1948 the Framingham Heart Study began monitoring the health of 5,209 people in one Massachusetts town, and the addition of second and third generations swelled those numbers to almost 15,000. The observations and data FHS has produced are credited with helping reverse an epidemic of heart disease and ushering in an era of preventive care. More recent work has probed for links between genetic variations and everything from blood pressure and cholesterol levels to heart attacks and stroke, as Proto reported in “One Town’s Treasure” (Winter 2008).
The pace of those discoveries is likely to slow now that the hallmark clinical exams that Framingham investigators conducted on participants every two years for the past 65 years will cease. As a result of the federal government’s automatic spending cuts, the National Heart, Lung, and Blood Institute (NHLBI) cut Framingham’s 2013 operating budget by 40%, or $4 million. In addition, when FHS’s contract expires in 2015, it is slated to be renewed for only two or three years.
Framingham investigators will continue to follow participants, but in lieu of physical exams, it will survey participants’ health status by phone or letter and mine Medicare hospital records and death certificates for clinical data. Physicals had been “the lifeblood of the study,” says Philip Wolf, who joined FHS in 1967 as a stroke researcher and recently stepped down as its principal investigator. “We measure participants’ coronary calcium levels and vascular stiffness to predict disease, we do MRI scans of the brain, and we were going to start measuring the microbiome. You can’t do those tests by e-mail or get such data from a death certificate.”
Still, forcing Framingham to adapt to a different research structure won’t harm its scientific value, suggests Michael Lauer, director of the division of cardiovascular sciences at NHLBI. “We’ve paused exams a number of times before in other epidemiological studies and it hasn’t jeopardized their scientific value,” he says.
There is concern among FHS investigators that this change is part of a larger trend that could make the personal interactions of its epidemiological model obsolete. The NIH is spending $100 million on the Big Data to Knowledge project, for example, to figure out how to collect research to draw conclusions from the analysis of huge pools of data. “This gives us an opportunity to make epidemiological studies bigger and better by collecting even more detailed genomic, epigenetic or metabolomic data,” says Lauer. But Wolf argues against moving too quickly. “Before closing down prospective epidemiological studies, we should see whether Big Data can reach the same conclusions our studies can.”
FHS has operated under the auspices of Boston University since 1971, and the study is now working through the university’s development office to raise money from private sources. “There is no intention for the study to end,” says Lauer. “Our goal is to figure out how to strengthen all the epidemiology studies that NHLBI supports, and we have no choice but to do it less expensively.”
Dispatches

What Makes a Kid Clumsy? More research into coordination disorders shows why some children are more prone to trip, fumble and spill the milk.

Eyes in the Sky Satellite data can be used to assess the health impact of dust storms and the spread of mosquito-borne diseases. Additional applications could be on the horizon.

Could This One Change Help Curb the Opioid Crisis? To prescribe an effective bridge to addiction treatment, emergency physicians must get special training and receive a waiver. Making that process easier—or eliminating the requirement altogether—could make a big impact.

One Thing Leads to the Next Robert Lefkowitz is best known for revealing the mechanism behind hundreds of drugs in use today. But he thinks of himself as a storyteller first and has a new book out to make his case.

Podcast: The Research Year That Was Medical research labs have faced a difficult stretch of closed buildings and competing priorities. Yet they have also produced milestone discoveries—and not only on COVID-19.

The Shape of Us Two milestone discoveries in protein modeling promise to change the fundamentals of drug discovery.

Universal Flu Vaccines Move Forward In the shadow of coronavirus vaccine development, another vaccine was making solid progress.

Top Stories 

The Neuroscience of Giving Up
Why do some people react poorly, even catastrophically, in emergency situations?